How is Glycogen Supercompensation Regulated in Human Skeletal Muscle (Supercomp)
Regulation of Glycogen Supercompensation in Human Skeletal Muscle
Nine healthy, moderately fit male volunteers participated in the study. The subjects gave written informed consent after having been informed of any possible risk and discomfort associated with the study. The study was approved by the regional ethics committee in Denmark (Journal number: H-4-2013-071) and performed in accordance with the Declarations of Helsinki II.
All subjects underwent 3 clinical investigations (day 1, day 2 and day 5) during a 5 day glycogen supercompensation regime. The subjects were asked to refrain from physical activity and to eat a controlled diet containing 60% carbohydrates (CHO) for 4 days prior to the initial experiments.
Upon arrival at the laboratory on day 1, the subjects performed one-legged knee extensor exercise for 1 hour at 80% of PWL interspersed by 5 min bouts at 90% of PWL. This was followed by interval exercise until exhaustion containing 4 min bouts starting at 100% PWL followed by 1 min at 50% of PWL. Upon cessation of exercise the subjects showered and rested in the supine position for 4 hours. Then a 120 min hyperinsulinemic euglycemic clamp was initiated by a bolus insulin injection (9.0 mU/kg, Actrapid, Novo Nordisk, Denmark) followed by continuous insulin infusion (1.42 mU/kg/min insulin) reaching a level of plasma insulin around 100 µU/mL (n=9). At least 2 hours before the insulin clamp, catheters were placed in both femoral, one antecubital and one dorsal hand vein. A heat pad was placed around the lower part of the arm and hand in order to "arterialize" blood drawn from the hand vein. Substrate uptake/release across the legs was calculated by multiplying the arterial-venous (AV) difference in blood substrate concentration by femoral arterial blood flow (measured by ultrasound, Philips DICOM). Blood glucose levels were maintained at the euglycemic predefined target by continuously adjusting the glucose infusion rate (GIR) (20% glucose solution; Fresenius Kabi, Sweden). Concurrent measures of substrate AV differences and blood flow were performed every 20 min. Muscle biopsies from m. vastus lateralis were obtained under local anaesthesia (3-5 ml of Xylocaine, 20 mg/ml.) in the basal- and insulin-stimulated state (120 min) by use of needle biopsy technique. Muscle specimen were frozen within 20 sec in liquid nitrogen and stored at -80°C for further analysis. A new incision was made for every biopsy and spaced 4-5 cm apart.
This insulin clamp procedure in combination with basal and insulin stimulated muscle biopsies was repeated in the rested state (without prior exercise) on day 2 and day 5. The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Capital Region
-
Copenhagen, Capital Region, Denmark, 2100
- Department of Nutrition, Exercise and Sports
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male
- BMI between BMI 20-25 kg/m2
- healthy and not using medication
- not smoking
- habitual physical activity level of 2 - 6 hours pr. week
- no incidence of diabetes, cardiovascular disease or other metabolic diseases in close family
Exclusion Criteria:
- female
- BMI below 20 and above 25 kg/m2
- using medication
- smoking
- habitual physical activity level below 2 h pr. week or above 6 hours pr. week
- incidence of diabetes, cardiovascular disease or metabolic disease in close family
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insulin action in skeletal muscle
Time Frame: 1 week
|
Insulin action in skeletal muscle was investigated during hyperinsulinemic euglycemic conditions by combining AV-difference with blood flow measurements.
|
1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Supercomp
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Sensitivity
-
NCT06766617CompletedInsulin Sensitivity/Resistance
-
NCT06772857Active, not recruitingInsulin Sensitivity/Resistance
-
NCT07109245RecruitingCognition | Healthy Controls | Brain Insulin Sensitivity
-
NCT04482374RecruitingEndothelial Dysfunction | Vascular Stiffness | Insulin Sensitivity/Resistance | Transgenderism
-
NCT02745613CompletedInsulin Sensitivity/Resistance
-
NCT01521806UnknownFocus of the Study is Insulin Sensitivity
-
NCT02524457UnknownInsulin Sensitivity and Lipid Metabolism
-
NCT01648478Completed
-
NCT04700241CompletedVascular Function | Nitrate | Brain Insulin-sensitivity
Clinical Trials on Glycogen Supercompensation
-
NCT04416204CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus
-
NCT02057731CompletedGlycogen Storage Disease
-
NCT01854242CompletedInflammatory Bowel Disease | Glycogen Storage Disease Type Ia
-
NCT04371237CompletedMuscle Soreness | Muscle Recovery | Glycogen Depletion
-
NCT04004676UnknownKetosis | Exercise Performance | Ketonemia
-
NCT03682861Unknown
-
NCT02042287Completed
-
NCT00111215CompletedBlood Coagulation Disorders | Blood Platelet Disorders | Menorrhagia | Hematologic Disease | Von Willebrand Disease